NRG1 fusions in breast cancer

NRG1 fusions in breast cancer

Abstract Background NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric receptor tyrosine kinase, and the gene fusions are thought to lead t...

Full description

Bibliographic Details
Main Authors: Karen D. Howarth, Tashfina Mirza, Susanna L. Cooke, Suet-Feung Chin, Jessica C. Pole, Ernest Turro, Matthew D. Eldridge, Raquel Manzano Garcia, Oscar M. Rueda, Chris Boursnell, Jean E. Abraham, Carlos Caldas, Paul A. W. Edwards
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Breast Cancer Research
Subjects:
NRG1 fusions
Breast cancer
NRG1
Clinically actionable
MDA-MB-175
Whole-genome sequencing
Online Access:https://doi.org/10.1186/s13058-020-01377-5

Internet

https://doi.org/10.1186/s13058-020-01377-5

Similar Items